Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives

Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Hypertension and renal mass reduction induce glomerular hypertension (GH), hyperfiltration (HF) and renal injury. GH may contribute to allograft loss in post-transplant hypertensive patients (PT × HT). HF and GH may be evaluated by renal response to acute protein intake (API). Since ACE inhibition may prevent GH, the effects of fosinopril (Fos) were evaluated in 10PT × HT on azathioprine and prednisone. Patients received 5 to 40 mg/day of Fos during 12 months.Baseline MAP (111.1 ± 2.9mm Hg) was significantly reduced by 10 to 12mm Hg, rising to 114.7 ± 2.7mm Hg after Fos was administered. GFR (63.7 ± 5.9 ml/min) decreased after 4 (48.1 ± 4.6, P